← FDA DRUG APPROVALS

FDA NDA · NDA212576

INQOVI

cedazuridine and decitabine

Sponsor: TAIHO ONCOLOGY

APPLICATION
NDA212576
TYPE
NDA
ORIGINAL APPROVAL
2020-07-07
LATEST ACTION
2026-05-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

INQOVI · ReferencePrescription
CEDAZURIDINE 100MG, DECITABINE 35MG · TABLET · ORAL

Approval history

2026-05-13Efficacy · Supplement 8 · standardLetterAP
2022-03-24Labeling · Supplement 3 · standardLetterAP
2020-07-07Type 1 - New Molecular Entity and Type 4 - New Combination · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →